Abstract Number: 0927 • ACR Convergence 2022
Review of 167,990 Same Day RAPID3, CDAI Scores for 61,312 Patients Receiving DMARD Treatment for Rheumatoid Arthritis; Evaluations of Disease Assessments and Treatment Discontinuation
Background/Purpose: Treatment efficacy for rheumatoid arthritis is often measured through disease assessments containing subjective input from the provider, the patient, or both. Here we compare…Abstract Number: 1210 • ACR Convergence 2022
Use of Biologic or Targeted Synthetic Disease Modifying Anti-rheumatic Drugs and the Risk of Lymphoma in Rheumatoid Arthritis
Background/Purpose: Epidemiologic studies suggest that disease duration and degree of inflammatory activity of rheumatoid arthritis (RA) are associated with lymphoma development [1]. Whether the decrease…Abstract Number: 1586 • ACR Convergence 2022
Sustained Remission Following the Discontinuation of Tofacitinib in Patients with Rheumatoid Arthritis (XANADU Study): A Multicenter, Prospective, and Randomized Controlled Study
Background/Purpose: To investigate sustained remission following the discontinuation of tofacitinib in patients with rheumatoid arthritis (RA).Methods: RA patients who had an inadequate response to methotrexate…Abstract Number: 1960 • ACR Convergence 2022
Impact of Delaying Initiation of Methotrexate by One Month on the Outcome of RA at One Year
Background/Purpose: It is recommended that vaccinations should be performed prior to start methotrexate (MTX) knowing that delaying initiation of background therapy may have an impact…Abstract Number: 2147 • ACR Convergence 2022
Cumulative Dose and Exposure Time to Methotrexate Were Not Shown to Be Predictors of Hepatic Fibrosis by Elastography – A Monocentric Cohort Study
Background/Purpose: Methotrexate is an immunomodulatory agentu sed in several inflammatory diseases, such as rheumatoid arthritis (RA), spondyloarthritis (SpA) or inflammatory bowel disease (IBD). Despite being…Abstract Number: 0113 • ACR Convergence 2022
Escalation to Biologics After Methotrexate Among US Veterans with Rheumatoid Arthritis Living in Rural versus Urban Areas
Background/Purpose: Timely diagnosis and initiation of appropriate treatments are imperative to improve outcomes for patients with rheumatoid arthritis (RA). Racial and ethnic disparities in RA…Abstract Number: 0306 • ACR Convergence 2022
Maintenance of Disease Activity and Treatment Persistence in Patients with Rheumatoid Arthritis Who Switched from Combination to TNF Inhibitor Monotherapy: Results from the Rheumatology Informatics System for Effectiveness (RISE) Registry
Background/Purpose: Data regarding the maintenance of disease activity (DA) and treatment persistence in patients (pts) who switched from combination therapy to monotherapy for the management…Abstract Number: 0571 • ACR Convergence 2022
National Rollout of a Medication Safety Dashboard to Improve Testing for Latent Infections Among Biologic/targeted Synthetic DMARD Users Within the Veterans Health Administration: Initial Results
Background/Purpose: Guidelines recommend testing for latent hepatitis B virus (HBV), hepatitis C virus (HCV), and tuberculosis (TB) infection prior to initiating biologics or targeted synthetic…Abstract Number: 0798 • ACR Convergence 2022
Uncovering the Relationship Between COVID-19 Outcome Severity and Rheumatic Disease
Background/Purpose: The COVID-19 pandemic has caused great concern amongst immunocompromised patients, especially those with rheumatic diagnoses. While much has been learned in the past two…Abstract Number: 0928 • ACR Convergence 2022
Use of Disease Modifying Anti-rheumatic Drugs and Risk of Multiple Myeloma in US Veterans with Rheumatoid Arthritis
Background/Purpose: Biologic (b) and targeted synthetic (ts) DMARDs used in the management of rheumatoid arthritis (RA) target inflammatory pathways implicated in the pathogenesis of multiple…Abstract Number: 1211 • ACR Convergence 2022
Impact of Change in Biologic Disease Modifying Antirheumatic Drug Therapy on Disease Activity Measures: Findings from a Large Contemporaneous Real-World Longitudinal Database of RA Patients
Background/Purpose: While many clinical trials provide direct comparisons between biologic disease modifying antirheumatic drugs (bDMARD) and nonbiologic DMARDs (nDMARD), there is a need to better…Abstract Number: 1590 • ACR Convergence 2022
Pain and Treatment Switching Among Patients in the CorEvitasTM Rheumatoid Arthritis Registry
Background/Purpose: For many patients with RA on targeted therapies, the chronic burden of pain leads to therapies being deemed suboptimally effective and may affect treatment…Abstract Number: 1981 • ACR Convergence 2022
Rho-GTPase Expression Recruits CD14+ Cells to Joints in Rheumatoid Arthritis and Predicts Good Response to JAK-inhibitor Treatment
Background/Purpose: While examining arthritis development in GGTaseI-deficient mice, we found that hyperactive Rho-GTPases regulate the thymic egress of CD4+ T cells to the peripheral lymphoid…Abstract Number: 2149 • ACR Convergence 2022
Cycling versus Swapping Strategies in Psoriatic Arthritis: Results from the Rheumatic Diseases Portuguese Register
Background/Purpose: This study aimed to compare the effectiveness and safety of switching to a second tumour necrosis factor alfa inhibitor (TNFi) – "cycling group" -…Abstract Number: 0136 • ACR Convergence 2022
Sarcoidosis Incidence After mTOR Inhibitor Treatment
Background/Purpose: Mechanistic target of rapamycin (mTOR) inhibitors are effective in animal models of granulomatous disease, but their benefit in patients with sarcoidosis is unknown. We…
- « Previous Page
- 1
- …
- 21
- 22
- 23
- 24
- 25
- …
- 40
- Next Page »